Abstract:Chemotherapy for cancer patients induces damaging tissue reactions along the epithelium of the gastrointestinal tract (GIT). This chemotherapy-induced mucositis (CIM) is a serious side effect of cytotoxic drugs, and several animal models of CIM have been developed, mainly in rodents and piglets, to help understand the progression of CIM and how to prevent it. Animal models allow highly controlled experimental conditions, detailed organ (e.g., GIT) insights, standardized, clinically relevant treatment regimens, and discovery of new biomarkers. Still, surprisingly few results from animal models have been translated into clinical CIM management and treatments. The results obtained from specific animal models can be difficult to translate to the diverse range of CIM manifestations in patients, which vary according to the antineoplastic drugs, dose, underlying (cancer) disease, and patient characteristics (e.g., age, genetics, and body constitution). Another factor that hinders the direct use of results from animals is inadequate collaboration between basic science and clinical science in relation to CIM. Here, we briefly describe CIM pathophysiology, particularly the basic knowledge that has been obtained from CIM animal models. These model studies have indicated potential new preventive and ameliorating interventions, including supplementation with natural bioactive diets (e.g., milk fractions, colostrum, and plant extracts), nutrients (e.g., polyunsaturated fatty acids, short-chain fatty acids, and glutamine), and growth factor peptides (e.g., transforming growth factor and glucagon-like peptide-2), as well as manipulations of the gut microbiota (e.g., prebiotics, probiotics, and antibiotics). Rodent CIM models allow well-controlled, in-depth studies of animals with or without tumors while pig models more easily make clinically relevant treatment regimens possible. In synergy, animal models of CIM provide the basic physiological understanding and the new ideas for treatment that are required to make competent decisions in clinical practice.

An overview of chemically induced rodent models for sporadic colorectal cancer: Histopathological and translational perspectives

Colorectal cancer murine models: Initiation to metastasis

Murine models of colorectal cancer: the azoxymethane (AOM)/dextran sulfate sodium (DSS) model of colitis-associated cancer

Overview of research progress and application of experimental models of colorectal cancer

Review of Animal Models of Colorectal Cancer in Different Carcinogenesis Pathways

The progress and challenges in modeling colorectal cancer and the impact on novel drug discovery

Recent advances in the development of transplanted colorectal cancer mouse models

A Novel CRISPR/Cas9-mediated Mouse Model of Colon Carcinogenesis

Inducible mouse models of colon cancer for the analysis of sporadic and inflammation-driven tumor progression and lymph node metastasis

A Novel Mouse Model for Colitis-Associated Colon Carcinogenesis Induced by 1,2-Dimethylhydrazine and Dextran Sulfate Sodium

Advances in Epigenetic Biomarker Research in Colorectal Cancer.

Preclinical models as patients’ avatars for precision medicine in colorectal cancer: past and future challenges

A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies

Modeling Colorectal Cancer Progression Through Orthotopic Implantation of Organoids

Preclinical three‐dimensional colorectal cancer model: The next generation of in vitro drug efficacy evaluation

Experimental mouse models for translational human cancer research

Microbiome-driven carcinogenesis in colorectal cancer: Models and mechanisms

Inflammation, Gut Microbiota, and Metabolomic Shifts in Colorectal Cancer: Insights from Human and Mouse Models

Hereditary cancer syndromes as model systems for chemopreventive agent development

Animal models of chemotherapy-induced mucositis: translational relevance and challenges

Insights from Human and Mouse Models